The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY).
D000014:Abnormalities, Drug-Induced; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002453:Cell Cycle / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004247:DNA / Q000096:biosynthesis; D004260:DNA Repair; D004261:DNA Replication; D004351:Drug Resistance; D006144:Guanazole / Q000494:pharmacology*; D006657:Histones / Q000096:biosynthesis; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D066298:In Vitro Techniques; D009153:Mutagens; D011720:Pyrazoles / Q000494:pharmacology*; D012262:Ribonucleoside Diphosphate Reductase / Q000037:antagonists & inhibitors*; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship; D014230:Triazoles / Q000494:pharmacology*
D006657:Histones; D009153:Mutagens; D011720:Pyrazoles; D014230:Triazoles; D004247:DNA; D012264:Ribonucleotide Reductases; D012262:Ribonucleoside Diphosphate Reductase; D006144:Guanazole; C000971:2,3-dihydro-1H-imidazo(1,2-b)pyrazole; D006918:Hydroxyurea